The Federal Court previously found that Apotex and Cobalt infringed Bayer’s valid patent for an oral contraceptive composition combining drospirenone and ethinyl estradiol (Bayer’s YAZ and YASMIN) (2016 FC 1013, as reported here). The Federal Court subsequently held that Bayer was entitled to elect between damages and an accounting of Apotex’s profits (2016 FC 1192, as reported here). In so holding, the Federal Court disagreed with Apotex’s argument that it, rather than Bayer, should be entitled to elect whether Bayer should be limited to recovering Apotex’s profits. The Federal Court of Appeal dismissed Apotex’s appeal of the latter decision, holding that “the proposition that the infringer of a patent can determine the remedy to which the patentee is entitled is an astounding proposition” (Apotex Inc v Bayer Inc, 2018 FCA 32). The Federal Court of Appeal affirmed that, under the Patent Act, a successful patentee always has a right to its damages, and only it has the right to elect an accounting of profits, subject to the court’s discretion.
Related Publications & Articles
-
Federal Court of Appeal dismisses appeal challenging amended basket of comparator countries in PMPRB Regulations
On December 5, 2022, the Federal Court of Appeal (FCA) dismissed Innovative Medicines Canada (IMC) and sixteen innovative pharmaceutical companies’ appeal.Read More -
Federal Court rejects pre-trial determination of a question of law about the nature of the section 8 but-for world
As previously reported, the Federal Court found Janssen’s Canadian Patent No. 2,661,422 (422 patent) – which relates to treatment of prostate cancer in humans by co-administration of abiraterone aceta...Read More -
Federal Court of Appeal restores Minister of Health’s decision to grant RUZURGI NOC despite FIRDAPSE data protection
The Federal Court found that subsection C.08.004.1(3) of the Food and Drug Regulations applied to prevent the Minister from issuing an NOC in view of the data protection granted to FIRDAPSE, a drug co...Read More